ArticleFrontiers in oncology2025
Case Report: Complete response with combination oncolytic virus immunotherapy in a patient with stage IV renal cell carcinoma-a promising innovative approach.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Metastatic renal cell carcinoma stage IV (RCC-IV) remains a therapeutic challenge, with an overall 5-year survival rate of 12%. Conventional chemotherapy and radiotherapy have shown relatively low efficacy in reducing morbidity and mortality, whereas innovative immunotherapies have demonstrated promising clinical results with fewer adverse events (AEs). Oncolytic virus (OV) immunotherapy has produced remarkable therapeutic effects in many solid tumors, including refractory and end-stage tumors, with intratumoral (IT) injection (IT-OV) suggested to enhance both efficacy and tolerability. We report the clinical course of a patient with RCC-IV who was treated over a period of 3 years with multiple IT injections of various OVs and another immunotherapeutic agent. A complete response-confirmed through periodic radiological surveillance and biopsies-was achieved without any serious side effects, hospital admissions, or surgical interventions throughout the entire treatment course. To our knowledge, this is the first documented case of complete remission of RCC-IV mediated by IT-OV therapy. The rationale and potential of IT-OV therapy as an innovative approach for treating RCC-IV are discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.